Old API Wind-down Ltd - Ordinary Shares ARLZQ

RE:RE:RE:RE:That's interesting...

[ConfidentDD]

Excellent DD. I came to this same analysis a different way, which was when I was boggled that ARZwas buying more drug products, and with debt. Putting the load on Yosprala to bring cash to carry new drug debt and interest. seems rushed. Why the rush? The trigger-happiness? Don't Pharm company execs ever want to produce a profit? I hope Adams isn't working on models that worked for him before, as these a challenged now.

mjh9413 wrote: What I found interesting were the comments by that 'real' healthcare expert Richard Evans on BNN last nite, when he made the point of explaining ( a point I have made here before) that it does not matter if a health company (he was talking about Concordia) says it has positive EBITDA when the only reason it is positive is the add back in of all their relatively high interest costs, without which it would be a NEGATIVE EBITDA.  ARZ's full qtrly gross interest costs after Toprol purchase and before any other borrowing, but not counting any offset from their cash position, will be about $6.4MM.  Hope we get indication of Yosprala sales BEFORE qtr report as it clearly will have to subsidize at least the initial Toprol (and also Zontivity) costs as well as the proposed and significant cost increases in salesforce costs. That IMO is the true picture of ARZ, with financial well-being hanging on Yosprala, for next 9 mos at least. I remain long about these levels but with downside limit.